Aggressive NK cell lymphomas: insights into the spectrum of NK cell derived malignancies

Quintanilla-Martı́nez, Leticia; Jaffe, Elaine S.

doi:10.1046/j.1365-2559.2000.01029.x

Cited by 27 publications

(23 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study also demonstrated clear genetic difference between ANKL and ENKL, suggesting that these are two distinct disease entities. This data supports the clinicopathologic features identified between ANKL and ENKL 188 . These differences may represent differences in ENKL between localized and advanced cases, but further studies are needed to clarify this issue.…”

Section: Genetic Features and Oncogenessupporting

confidence: 88%

Leukemia and Lymphoma of Natural Killer Cells

Suzuki

2005

J Clin Exp Hematopathol

View full text Add to dashboard Cite

Malignant hematolymphoid disorders arising from NK cells have become widely recognized over the past decade. The two forms of NK-cell malignancy, aggressive NK-cell leukemia (ANKL) and extranodal NK-cell lymphoma of nasal type (ENKL) are both characterized by the proliferation of tumor cells with an NK-cell like immunophenotype. ANKL usually presents with bone marrow tumor cells accompanied by circulating leukemic cells, and hepatosplenomegalay is a common clinical feature. ENKL most frequently affects the nasal or paranasal regions, with cutaneous involvement also being common. Approximately 70 percent of ENKL present with localized tumor cells, and follow an indolent clinical course, but, in advanced cases, tumors rapidly expand and are frequently fatal. Tumor cells from both ANKL and ENKL are surface CD3 − and CD56 + but differ in their expression of CD16. Epstein-Barr virus (EBV) is found in most cases of NK-cell leukemia/lymphoma, suggesting an oncogenic role, but patients may have biclonal or polyclonal populations of malignant cells based on differential EBV genome incorporation. NK-cell neoplasms are frequently resistant to chemotherapy due to p-glycoprotein expression and associated multidrug resistance. The prognoses of both localized and advanced stages of NK-cell malignancies are worse than most other lymphoid malignancies, but studies are currently underway to assess the safety and efficacy of novel chemoradiotherapy regimens for the treatment of these neoplasms.

show abstract

Section: Genetic Features and Oncogenessupporting

confidence: 88%

Leukemia and Lymphoma of Natural Killer Cells

Suzuki

2005

J Clin Exp Hematopathol

View full text Add to dashboard Cite

show abstract

“…ANKL occurs in a younger population (median: 42 years old) and more frequently shows lymphadenopathy and hepatosplenic involvement than does nasal-type NK-cell lymphoma. 48 The exclusive expression of CD2 and CD56 and the absence of CD3 and TCRs in ANKL reflect its NK-cell origin. A high expression rate of CD16 (75%) is also characteristic of ANKL.…”

mentioning

confidence: 99%

Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells

et al. 2004

View full text Add to dashboard Cite

show abstract

“…The median survival in those patients with localized nasal-type disease was 12 months, compared with 2 months in the ANKL. The authors, like others [5,22,23], consider aggressive multi-organ NK lymphoma/leukemia to be a pathological condition distinct from advanced stage localized NK lymphoma.…”

Section: Discussionmentioning

confidence: 93%

Aggressive Natural Killer Cell Leukemia/Lymphoma: Case Report, use of Telesynergy™ and Review of the Literature

Murdock

Jaffe

Wilson

et al. 2004

Leukemia & Lymphoma

View full text Add to dashboard Cite

Natural killer cell malignancies, although increasingly recognized, remain rare tumors within the USA and Europe. They are somewhat more common in Asia, and have been best characterized within this population. We present a case of a young Caucasian woman who presented acutely with an aggressive natural killer cell leukemia/lymphoma. Use of Telesynergy technology enabled a transatlantic telemedicine conference with colleagues in a center of expertise. Unfortunately the patient was ultimately refractory to both conventional chemotherapy and Campath-1H and her disease course was fulminant, as has been described previously in this condition. We review the possible therapeutic options for this extremely aggressive malignancy and briefly discuss our center's experience of telemedicine technology.

show abstract

Aggressive NK cell lymphomas: insights into the spectrum of NK cell derived malignancies

Cited by 27 publications

References 31 publications

Leukemia and Lymphoma of Natural Killer Cells

Leukemia and Lymphoma of Natural Killer Cells

Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells

Aggressive Natural Killer Cell Leukemia/Lymphoma: Case Report, use of Telesynergy™ and Review of the Literature

Contact Info

Product

Resources

About